DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Oncology Market Access in Key European Countries: Challenges and Opportunities

 

Oncology Market Access in Key European Countries: Challenges and Opportunities

As new and exciting oncology therapies launch on the market in Europe, the options for patients increase—as do payer concerns about their budgets. While innovative therapies may be highly beneficial for patients, they also place considerable pressure on European healthcare budgets. Consequently, payers in Europe use a variety of means to contain costs when it comes to oncology, from national-level health technology assessments to limiting patient populations that can receive a new therapy. However, payers must delicately balance cost containment measures with clinical need, as well as with public opinion and political pressure to improve patient access to new life-saving therapies.

This white paper will examine some of the more influential market access shifts and changes that we are seeing for oncology, ultimately deciding whether each factor is a market access challenge for developers, or an opportunity.